NCT00162006View on ClinicalTrials.gov

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2003

Primary Completion Date

December 3, 2003

Study Completion Date

December 3, 2003

Conditions

Immune Thrombocytopenic Purpura (ITP)

Interventions

DRUG

Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

Trial Locations (11)

Unknown

Brno

Hradec Králové

Olomouc

Prague

Giessen

Halle

Debrecen

Győr

Szeged

Szombathely

Lodz

All Listed Sponsors

lead

Baxalta now part of Shire

INDUSTRY

NCT00162006 - Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter